GGrantIndex
← Leaderboards

Yael P Mosse

Children'S Hosp Of Philadelphia

$12,182,604
Attributed
$12,182,604
Total exposure
5
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.4M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,182,604 · 5

By mechanism

R01$5,635,629 · 1
U01$3,549,742 · 1
P01$2,315,153 · 2
K08$682,080 · 1

Top collaborators

No co-investigators on record.

Most similar at Children'S Hosp Of Philadelphia

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms

Research focus

Malignant NeoplasmsTumorNeuroblastomaMalignant Childhood NeoplasmChildPre-ClinicalOncogenicClinical TrialsOncogenesMutationDiagnosisClinicBaseHigh RiskRelapseUnited States National Institutes Of HealthMissionEvidence BaseDesignTumorigenesisResponseChemotherapyMolecularImproved Outcome

Grant awards (32)

NCI Pediatric In Vivo Testing Program: Neuroblastoma$712,799
U01 · FY2025 · CA · contact PI
Targeting evolving therapy resistance$407,872
P01 · FY2025 · CA · contact PI
NCI Pediatric In Vivo Testing Program: Neuroblastoma$712,799
U01 · FY2024 · CA · contact PI
Targeting evolving therapy resistance$400,151
P01 · FY2024 · CA · contact PI
NCI Pediatric In Vivo Testing Program: Neuroblastoma$712,800
U01 · FY2023 · CA · contact PI
Targeting Oncogenic ALK Signaling in Neuroblastoma$418,000
R01 · FY2023 · CA · contact PI
NCI Pediatric In Vivo Testing Program: Neuroblastoma$698,544
U01 · FY2022 · CA · contact PI
Targeting Oncogenic ALK Signaling in Neuroblastoma$409,640
R01 · FY2022 · CA · contact PI
NCI Pediatric In Vivo Testing Program: Neuroblastoma$712,800
U01 · FY2021 · CA · contact PI
Targeting Oncogenic ALK Signaling in Neuroblastoma$401,461
R01 · FY2021 · CA · contact PI
Proj 1 - Targeting Evolving Therapy Resistance$320,207
P01 · FY2021 · CA · contact PI
Targeting Oncogenic ALK Signaling in Neuroblastoma$401,600
R01 · FY2020 · CA · contact PI
Proj 1 - Targeting Evolving Therapy Resistance$302,817
P01 · FY2020 · CA · contact PI
Targeting Oncogenic ALK Signaling in Neuroblastoma$437,836
R01 · FY2019 · CA · contact PI
Targeting Evolving Therapy Resistance$269,130
P01 · FY2019 · CA · contact PI
Targeting Oncogenic ALK Signaling in Neuroblastoma$374,304
R01 · FY2018 · CA · contact PI
Targeting Evolving Therapy Resistance$286,843
P01 · FY2018 · CA · contact PI
Targeting Oncogenic ALK Signaling in Neuroblastoma$374,324
R01 · FY2017 · CA · contact PI
Targeting Evolving Therapy Resistance$328,133
P01 · FY2017 · CA · contact PI
Targeting Oncogenic ALK Signaling in Neuroblastoma$374,344
R01 · FY2016 · CA · contact PI
Targeting Oncogenic ALK Signaling in Neuroblastoma$378,479
R01 · FY2015 · CA · contact PI
Targeting Oncogenic ALK Signaling in Neuroblastoma$404,266
R01 · FY2014 · CA · contact PI
Targeting Oncogenic ALK Signaling in Neuroblastoma$311,233
R01 · FY2013 · CA · contact PI
Targeting Oncogenic ALK Signaling in Neuroblastoma$331,098
R01 · FY2012 · CA · contact PI
Targeting Oncogenic ALK Signaling in Neuroblastoma$331,098
R01 · FY2011 · CA · contact PI
Targeting Oncogenic ALK Signaling in Neuroblastoma$343,973
R01 · FY2010 · CA · contact PI
Targeting Oncogenic ALK Signaling in Neuroblastoma$343,973
R01 · FY2009 · CA · contact PI
GENOMICS OF HUMAN NEUROBLASTOMA$124,800
K08 · FY2009 · CA · contact PI
GENOMICS OF HUMAN NEUROBLASTOMA$139,320
K08 · FY2008 · CA · contact PI
GENOMICS OF HUMAN NEUROBLASTOMA$139,320
K08 · FY2007 · CA · contact PI
GENOMICS OF HUMAN NEUROBLASTOMA$139,320
K08 · FY2006 · CA · contact PI
GENOMICS OF HUMAN NEUROBLASTOMA$139,320
K08 · FY2005 · CA